Freedom of Information Request: 0583 2019/20
University Hospitals Birmingham NHS Foundation Trust (UHB) completed a merger by acquisition of Heart of England NHS Foundation Trust (HEFT) on 1st April 2018. Due to historical differences in data collection/reporting across UHB and the former Heart of England NHS Foundation Trust this response has been provided by hospital site.
Queen Elizabeth Hospital Birmingham (QEHB)
- Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
11
- Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
Locally advanced: 1
Recurrent metastatic: 0
Unknown: 0
- Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
Carboplatin (only or in combination with 5-FU) – 2
Cisplatin (only or in combination with 5-FU) - 1
Cetuximab with/without chemotherapy – 1
Cetuximab with radiotherapy – 0
Pembrolizumab monotherapy – 0
Pembrolizumab with chemotherapy – 0
Nivolumab – 0
Docetaxel (only or in combination with 5-FU) – 0
Fluorouracil (5FU) – 1
Radiotherapy only – 5
Other – 1
Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
University Hospitals Birmingham – We can confirm that we have 8 studies open at present in the head and neck cancer team
| Short Title
|
Site
|
Site Status
|
Site Recruitment | |
| Accelerated Platform | QEHB | Open | 159 | |
|
QEHB | Open | 27 | |
|
QEHB | Closed to recruitment – in follow up | 4 | |
| CheckMate 651: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 651 | QEHB | Closed to recruitment – in follow up | 5 | |
| CompARE Trial | QEHB | Open | 45 | |
| Observational study in R/M SCCHN V18Dec2018 | QEHB | Open | 0 | |
| PATHOS | QEHB | Open | 4 | |
| SEND | QEHB | Closed to recruitment – in follow up | 20 |
- Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
0 FOR ALL
Aflibercept
Bevacizumab
Capecitabine
CAPIRI
CAPOX
Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Irinotecan
FOLFIRI
FOLFOX
Oxaliplatin
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab
Raltitrexed
Ramucirumab
Regorafenib
Sorafenib
5FU only
Tegafur Uracil + 5FU
Trifluridine–tipiracil
XELOX
Other
- Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:
Sunitinib – 2
Avelumab + Axitinib – 0
Axinitib – 0
Cabozantinib – 0
Everolimus – 0
Lenvantinib + Everolimus – 0
Nivolumab – 1
Nivolumab + Ipilimumab – 0
Pazopanib – 1
Pembrolizumab + Axitinib – 0
Sunitinib – 0
Temsirolimus – 0
Tivozanib – 0
- Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
University Hospitals Birmingham – We can confirm that we have 2 studies open at present for patients with Renal Cell Cancer
| Short Title
|
Site
|
Site Status
|
Site Recruitment |
| SORCE | QEHB | Open | 0 |
| STAR Standard vs Modified Drug Therapy in Renal Cancer | Heartlands Hospital | Closed to recruitment – in follow up | 3 |
Heartlands, Good Hope and Solihull Hospitals (HGS)
- Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma)?
Not Applicable
- Of these patients how many are locally advanced and how many are recurrent and/or metastatic head and neck cancer patients?
Not Applicable
- Within your health trust how many patients have been treated in the past 6 months for head and neck cancer (Squamous cell carcinoma) with the following agents?
Not Applicable
Carboplatin (only or in combination with 5-FU)
Cisplatin (only or in combination with 5-FU)
Cetuximab with/without chemotherapy
Cetuximab with radiotherapy
Pembrolizumab monotherapy
Pembrolizumab with chemotherapy
Nivolumab
Docetaxel (only or in combination with 5-FU)
Fluorouracil (5FU)
Radiotherapy only
Other
Does your health trust participate in any ongoing clinical trials for the treatment of head and neck cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
University Hospitals Birmingham – We can confirm that we have 8 studies open at present in the head and neck cancer team
| Short Title
|
Site
|
Site Status
|
Site Recruitment | |
| Accelerated Platform | QEHB | Open | 159 | |
|
QEHB | Open | 27 | |
|
QEHB | Closed to recruitment – in follow up | 4 | |
| CheckMate 651: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 651 | QEHB | Closed to recruitment – in follow up | 5 | |
| CompARE Trial | QEHB | Open | 45 | |
| Observational study in R/M SCCHN V18Dec2018 | QEHB | Open | 0 | |
| PATHOS | QEHB | Open | 4 | |
| SEND | QEHB | Closed to recruitment – in follow up | 20 |
- Within your health trust how many patients have been treated in the past 6 months with the following agent for colorectal cancer [CRC];
Aflibercept – 0
Bevacizumab – 0
Capecitabine – 28
CAPIRI
CAPOX
Cetuximab not in combination with FOLFIRI or FOLFOX
Cetuximab in combination with FOLFIRI
Cetuximab in combination with FOLFOX
Irinotecan – 2
FOLFIRI
FOLFOX
Oxaliplatin
Panitumumab not in combination with FOLFIRI or FOLFOX
Panitumumab in combination with FOLFIRI
Panitumumab in combination with FOLFOX
Nivolumab – 1
Raltitrexed
Ramucirumab
Regorafenib
Sorafenib
5FU only – 8
Tegafur Uracil + 5FU
Trifluridine–tipiracil
XELOX
Other
- Within your health trust how many patients have been treated in the past 6 months with the following agent for Renal Cell Carcinoma:
Sunitinib
Avelumab + Axitinib – 4
Axinitib
Cabozantinib – 8
Everolimus
Lenvantinib + Everolimus
Nivolumab – 7
Nivolumab + Ipilimumab – 6
Pazopanib – 15
Pembrolizumab + Axitinib
Sunitinib – 7
Temsirolimus
Tivozanib
- Does your health trust participate in any ongoing clinical trials for the treatment of renal cell cancer patients, if so how many patients are currently taking part in clinical trials / what is the name/s of the trials?
University Hospitals Birmingham – We can confirm that we have 2 studies open at present for patients with Renal Cell Cancer
| Short Title
|
Site
|
Site Status
|
Site Recruitment |
| SORCE | QEHB | Open | 0 |
| STAR Standard vs Modified Drug Therapy in Renal Cancer | Heartlands Hospital | Closed to recruitment – in follow up | 3 |
